NCT02685293View on ClinicalTrials.gov

Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe COPD

PHASE3TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

December 9, 2016

Primary Completion Date

June 6, 2018

Study Completion Date

June 6, 2018

Conditions
COPD
Interventions
DRUG

GFF MDI (PT003)

Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)

DRUG

Placebo MDI

Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol

Trial Locations (1)

35294

Research Site, Birmingham

Sponsors
All Listed Sponsors
lead

Pearl Therapeutics, Inc.

INDUSTRY